Not Yet RecruitingPhase 2

Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters Liver Enzymes, Ultrasound, Elastography and Adipokines in Same Cases) in Patients With Metabolic Associated Steatotic Liver Disease.

Croatia114 participantsStarted 2025-07-01

Plain-language summary

Scientific hypothesis: the use of a synbiotic preparation with a multi-strain probiotic in patients with MASLD can lead to a decrease in non-invasive elastographic parameters of hepatic steatosis and fibrosis and an improvement in liver function. The main objective of this study is to examine whether the test product affects the improvement of liver function measured by elastographic parameters or at least the prevention of further disease progression. The goal of this clinical trial is to learn if sinbiotics works to improve liver function in adult patients with MASLD The main questions it aims to answer are: Does sinbiotic lowers elastographic parameters od steatosis and fibrosis? Does it change liver function by lowering liver enzymes, blood lipids and sugar? Can sinbiotics lower CV risks and improve quality of life? Researchers will compare sinbiotic to a placebo (a look-alike substance that contains no drug) to see if sinbiotic works in MASLD patients. Participants will: Take sinbiotic or a placebo every day (td) for 9 months Visit the clinic once every 3 months for checkups, and at the begining and after 9 months for blood tests and US with elastography Keep a diary of their symptoms, diet, activity

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * MASLD confirmed by ultrasound and elastography with CAP \> 260 dB/m/MHz; * other causes of chronic liver disease excluded and/or diagnosis confirmed by liver biopsy, * presence of metabolic syndrome according to the definition of the International Diabetes Federation (IDF): waist circumference for women over 80 cm or over 94 cm for men, and at least two of the other criteria (treated hypertensive or blood pressure \> 130/85 mmHg determined during inclusion; treated diabetic or newly detected fasting serum glucose levels \> 5.6 mmol/l; treated dyslipidemia or newly detected serum triglyceride levels \> 1.7 mmol/L or HDL \< 1.29 mmol/L for women/\< 1.03 mmol/L for men), * signed informed consent. Exclusion Criteria: * pregnancy, * significant alcohol intake (\>30g/day in men, \>20g/day in women), * presence of autoimmune, viral, cholestatic (primary biliary cholangitis, primary sclerosing cholangitis, obstructive biliary tree diseases) or metabolic (hemochromatosis, Wilson) causes of chronic liver disease, transplant patients, malignant diseases, free fluid in the abdomen, significant small bowel resections, * signs of liver cirrhosis or LSM\>13 kPa measured TE, * use of medications that can promote the development of steatosis (e.g. corticosteroids, high doses of estrogen, methotrexate, amiodarone, valproate), and medications that can affect the composition of the microbiota for at least 3 months before the start of the study (antibiotics and probiotic…

What they're measuring

change in the controlled attenuated coefficient CAP (dB/m/MHZ) for steatosis

Timeframe: at baseline and after 270 days of intervention*

change in liver stiffness measurement (LSM) (kPa) measured by transient elastography for fibrosis

Timeframe: at baseline and after 270 days of intervention

Trial details

NCT IDNCT07025980

SponsorEva Cubric

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-07-31

Contact for this trial

Eva Cubric, doctor of medicine

+38522641465 gastroenterologija@bolnica-sibenik.hr